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Infra-luciferin, an alkene linked analogue of luciferin, gives bioluminescence emission >700 nm and has the
potential to be used for multiparametric in vivo imaging. We report here a high yielding, scalable and
convergent synthesis of infra-luciferin which will allow the synthesis of other conjugated luciferins for
investigation in near-infrared bioluminescence imaging. We demonstrated this potential by using the
new route to synthesise a diene linked analogue of luciferin, the ﬂuorescent and bioluminescent
properties of which were compared to those of D-luciferin and infra-luciferin. We found that extension
of conjugation to a diene linker resulted in the speciﬁc bioluminescence activity being reduced by 3–4
orders of magnitude compared to D-luciferin. Analogous to its ﬂuorescence emission spectrum, the
diene linked analogue exhibited two peaks in its bioluminescence spectrum, the major one being slightly
blue-shifted compared to natural D-luciferin, and a minor peak at ca. 800 nm. The ﬂuorescence
quantum yield and pH dependence of ﬂuorescence were also determined.Introduction
Noninvasive bioluminescence imaging has been critical in
understanding biological phenomena in detecting disease, and
is essential to probe cells and discrete molecular events within
living systems. Imaging using the bioluminescence of rey
luciferase has become an important tool both in vitro1 and in
vivo,2 in particular for the tracking of tumour cells in model
animals, diagnostic assays and sequencing. One of the most
well studied and most widely used systems is rey luciferase
and its substrate D-luciferin (1) which in the presence of O2 and
ATP emits yellow light of lmax 558 nm (Fig. 1).3 This system has
emerged as themost popular noninvasive imaging tool because,
unlike uorescent probes, luciferases do not require incident
radiation to produce light, which means the background signal
for bioluminescence imaging in vivo is negligible. The high
signal to noise ratio lends itself to sensitive imaging applica-
tions within complex environments. In addition D-luciferin (1)
is relatively stable, non-toxic and can penetrate most cell and
tissue types following injection. The common luciferaseege London, 20 Gordon Street, London,
.uk
iﬀ, Sir Martin Evans Building, Museum
ridgeshire Business Park, Bartholomew's
(ESI) available: General experimental
a and optical imaging details. See DOI:
hemistry 2017enzymes can be purchased commercially and standard biolu-
minescence detectors are available in research centres.4
Unfortunately absorption of visible light by haemoglobin
and melanin restricts image resolution and signal penetration
of the light from D-luciferin (1).5 Light above l 600 nm is more
tissue penetrant, but despite mutations to luciferase and the
synthesis of luciferin analogues it remains quite diﬃcult to
generate genuine bioluminescent emissions in the near
infrared (nrIR), which would improve in vivo imaging.6 InspiredFig. 1 Fireﬂy D-luciferin and synthetic extended conjugation
analogues.
RSC Adv., 2017, 7, 3975–3982 | 3975
Fig. 2 Proposed disconnection for the rapid synthesis of conjugated
luciferin analogues.
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View Article Onlineby the work of Maki and co-workers, who demonstrated the
eﬀect that extendedp-conjugation can have on bioluminescence
emission wavelength of synthetic luciferin derivatives such as 2
and 3,7 we synthesised infra-luciferin (4) with an alkene linker
between the benzothiazole and thiazoline fragments (Fig. 1).
This gave bioluminescence emission of lmax ¼ 706 nm with
a luciferase mutant x5 S284T and is the furthest red shied form
of bioluminescence reported to date.8 Akin to natural luciferin,
infra-luciferin (4) exhibited pH dependent uorescence spectra
and exhibited bioluminescence of diﬀerent colours with
diﬀerent engineered Fluc enzymes. Maki and coworkers noted
nearly a 100 nm red shi of emitted light when adding another
double bond to 2 to form 3, together with a 3-fold drop in
bioluminescence activity.7b Similarly we wondered what eﬀect an
extra alkene linker in infra-luciferin (4) would have on its
bioluminescence characteristics. We report here an improved
synthesis of infra-luciferin (4) that enables the synthesis of
analogues. To demonstrate this the synthesis of the diene linked
luciferin 5, akin to 3, was accomplished and the uorescent and
bioluminescent properties of 5 were evaluated and compared to
those of D-luciferin (1) and infra-luciferin (4).
Results and discussion
Our previously reported synthesis of infra-luciferin (4) gave
methyl ester 6 in 17% yield over 9 steps from commercially
available 6-methoxy-1,3-benzothiazol-2-amine (Scheme 1).8
However, this route suﬀered from some diﬃculties. The cycli-
sation and deprotection steps were capricious upon scale up
and only small amounts of the infra-luciferin ester could be
isolated. The route is linear so there are no common interme-
diates which could be used to synthesise other novel conjugated
luciferins with additional functionality. Finally, the carboxyl
group of infra-luciferin (4) is incredibly sensitive to epimeriza-
tion, presumably due to the extended delocalization making
enolisation easier. We wanted a more eﬃcient convergent
synthesis of infra-luciferin (4) which would also enable the
rapid synthesis of other novel stretched luciferins.
We focused upon developing a racemic synthesis of infra-
luciferin (4) as, in addition to being more facile than anScheme 1 Previous reported route to infra-luciferin (4).
3976 | RSC Adv., 2017, 7, 3975–3982enantiopure synthesis, we were interested in whether the
racemic material could be used for bioluminescence imaging
due to the much lower cost and availability of racemic amino
acids compared to the unnatural D-amino acids. As the thiazo-
line in luciferin is known to be crucial for light emission9 we
thought that this functionality could be installed using a Wittig
type reaction, which would allow for a number of analogues
with modied benzothiazoles or additional alkene linkers to be
synthesised (Fig. 2).
Masson et al. have synthesised phosphonylated thiazoline
Wittig reagents, albeit without an enolisable proton, and uti-
lised these compounds in Wittig reactions.10 Applying
analogous methodology, ethyl 2-(diethoxyphosphoryl)ethane-
dithioate (7) (synthesised in 2 steps according to published
literature procedures)11 was reacted with serine methyl ester to
give the intermediate hydroxysubstituted thioamide (8) in 95%
yield aer column chromatography (Scheme 2). It was found
that phosphonate 7 degraded upon storage even at 20 C,
however, thioamide 8 was found to be stable for at least 4
months at 20 C, so upon isolation of 7 it was reacted
immediately to give 8. Cyclisation of 8 using a Mitsonubu
reaction gave novel thiazoline 9 in 85% yield. These steps were
readily scalable and could be performed on a multi-gram scale.
The synthesis of the necessary aldehyde coupling partner
(Fig. 2) required the use of a protecting group for what would
ultimately become the 60-hydroxyl group of infra-luciferin (4).
Removal of the benzyl group in our previous synthesis (SchemeThis journal is © The Royal Society of Chemistry 2017
Scheme 2 Synthesis of thiazoline 9.
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View Article Online1) to form 6 had proved problematic upon scale up so diﬀerent
protecting groups were investigated. The methoxy-ethoxy-
methyl protecting group (MEM) had been successfully used by
Branchini and coworkers to protect the 60-hydroxyl group of an
N-acyl sulfamate analogue of luciferyl-adenylate and depro-
tected using triuoroacetic acid, which did not interfere with
their particular luciferin analogue.12 This example was with
a derivative of dehydroluciferin, which is resistant to oxidative
decomposition at the sensitive C-4 position because it is part of
a thiazole ring. We anticipated that the acidic conditions
required for removal, coupled with the expedient work up of
simple evaporation, if carried out in an oxygen free atmosphere,
should deliver the required thiazoline ring with the C-4 proton
intact. In addition the MEM protecting group could be removed
at a late stage aer all other functional group manipulations
had been performed, so as to minimize any oxidation or
degradation of the relatively sensitive thiazoline ring.
The requisite MEM protected aldehyde 10 was prepared by
standard MEM protection of 6-hydroxybenzothiazole (73%) fol-
lowed by low temperature metalation of the thiazole ring and
addition of DMF (87%). Attempted formation of infra-luciferin (4)
directly by treatment with Horner–Wadsworth–Emmons reagent
9 using DBU and LiCl was unsuccessful.9 The use of NaH as an
irreversible base in this Horner–Wadsworth–Emmons reaction
gave trace quantities of protected infra-luciferin 12 and multiple
unassigned products. However, the desired alkene 12 could be
formed using nBuLi in a low 23% yield.
To overcome these problems the Horner–Wadsworth–
Emmons reaction was performed using the hydroxysubstitutedScheme 3 Convergent synthesis of infra-luciferin (4) and novel diene lu
This journal is © The Royal Society of Chemistry 2017thioamide 8 with MEM-aldehyde 10 (Scheme 3). The use of
DBU/LiCl gave the alkene 11 in 63% yield. This compound was
used immediately as it was susceptible to degradation. Attempted
cyclisation using DEAD/PPh3 only gave undesired thiazole. Under
optimized conditions the use of DAST, which had previously
been used by Nicolaou to form a thiazoline,13 gave 12 in high 94%
yield and as a single pure compound aer chromatography.
When forming the thiazoline, and in all resultant steps, reaction
solvents were sparged with argon prior to use to minimize the
amount of oxygen present and hence prevent thiazole formation.
Thiazole formation in D-luciferin gives dehydroluciferin which is
known to inhibit the luciferase enzyme.14 We decided it was
prudent to minimize oxidation of the thiazoline in the more
conjugated derivatives. The MEM protecting group of 12 was
removed using TFA to give 6 in 97% yield and nally the free acid
could be isolated by treatment of 6 with LiOH to give infra-
luciferin (4) in 92% yield. Insuﬃcient care in reducing contact
of the thiazoline with air led to contamination of either 6 or infra-
luciferin (4) with the corresponding dehydro species which could
not be separated. Small quantities (5–10%) of the dehydro
materials were identied from the appearance of the thiazole
proton at d 8.21 (thiazole acid) and d 8.41 (thiazole ester) in the 1H
NMR spectrum. Pure 12 could be carefully treated with TFA and
then LiOH under optimized reaction conditions to give uncon-
taminated, spectroscopically pure infra-luciferin (4) by 1H and
13C NMR. As a solid this material is bench stable in air for days
and stable indenitely if stored in a freezer under N2. Stock
solutions of infra-luciferin (4) would gradually develop small
(5%) amounts of dehydro material over weeks. This new routeciferin analogue 5.
RSC Adv., 2017, 7, 3975–3982 | 3977
Table 1 Fluorescence properties of luciferin and 20-2 stretched
racemic free acids of analogues. All compounds measured in a Tecan
Inﬁnite spectrometer with at 50 mM in TEM buﬀer (pH 7.8) (+/5 nm).
For quantum yields, absorptions measured at 50 mM (pH 7.8) of 100 ml,
which are all less than 0.1 AU to avoid inner ﬁlter eﬀects. Eosin Y dye
used as a standard (490 nm excitation and 0.67 QY value) in basic
ethanol16
Compound
Excitation lmax
(nm)
Emission lmax
(nm)
Fluorescence
quantum yield
1 336 538 0.50
4 365 600 0.27
5 372 650, 505 0.17
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View Article Onlinereduces the number of linear steps with an overall yield of 31%,
can be scaled, and importantly the phosphonate 8 has the
potential to become a common intermediate in the synthesis of
other conjugated luciferins.
To further investigate extended conjugation in this analogue
we prepared the diene linked compound 5 by rst treating
MEM-aldehyde 10 with (triphenylphosphorarylidene)acetalde-
hyde to give diene 13 before treatment with 8. The Horner–
Wadsworth–Emmons reaction gave a lower yield with this
analogue (29%). Subsequent reactions analogous to the
synthesis of infra-luciferin (4) gave methyl ester 16 in similar,
but slightly lower yields (Scheme 3). The use of LiOH to depro-
tect the ester gave new analogue 5 but in an unoptimised yield of
35%. In comparison to the synthetic route to prepare infra-
luciferin (4), as soon as extra conjugation was introduced into
13, reactions from then on suﬀered from increased quantities of
byproducts. These contained no alkene signals and we speculate
that the substrates or reaction intermediates are susceptible toFig. 3 (a) Fluorescence emission spectra of D-luciferin (1) (green line), in
spectra, (b) pH dependence of ﬂuorescence spectra of D-luciferin (1) (3
(369 nm excitation) measured in 5 nm increments.
3978 | RSC Adv., 2017, 7, 3975–3982conjugate addition of nucleophilic species present in the reac-
tion conditions. We also found the more conjugated thiazoline
to be extremely sensitive to oxidation by air. Any manipulation
of the nal product 5 introduced varying degrees of the corre-
sponding thiazole. Consequently saponication with LiOH was
conducted swily and the material evaporated to dryness and
used as soon as possible in the bioluminescence assay.Fluorescence spectra of 20-2 alkene substituted luciferins
The uorescence excitation and emission lmax values of luciferin
(1) and racemic analogues, infra-luciferin (4) and 5 were
measured (Table 1) at pH 7.8 using a Tecan Innite M200
instrument (Thermo Fisher Scientic, MA, USA). Natural D-lucif-
erin (1) has a uorescence excitation lmax of 336 nm, while infra-
luciferin (4) and 5 display lmax 365 nm and 372 nm, respectively.
Therefore, while addition of a single central alkene linker in
infra-luciferin (4) red-shis the excitation spectra by 29 nm,
addition of another alkene (5) results in only a further 7 nm shi.
The uorescence emission spectra of D-luciferin (1), infra-
luciferin (4) and 5 displayed lmax of 538, 600 and 650 nm,
respectively (Fig. 3a). Thus the diﬀerences between the lmax of
emission spectra are larger than the excitation spectra, with an
increase of 62 nm due to the addition of one linker (4) and
a further 50 nm with the addition of another (5). The stretched
analogues also gave higher Stokes' shis than D-luciferin (1) (202
nm). The additional single alkene in infra-luciferin (4) increases
the Stokes' shi by 33 nm and the double alkene linker 5
increases by 76 nm relative to D-luciferin (1), which can be
explained by higher vibrational freedom of the larger molecules.
The uorescence quantum yield of the native molecules, though
not the oxyluciferin forms, can be useful,15 here indicating thatfra-luciferin (4) (red line) and 5 (black line). Dotted lines are normalized
30 nm excitation), (c) infra-luciferin (4) (352 nm excitation), and (d) 5
This journal is © The Royal Society of Chemistry 2017
Fig. 4 Quantiﬁcation of light emission of luciferin and analogues with wild-type Photinus pyralis luciferase. 2 mMATPwas added to 0.17 mMpure
Flucs mixed with 150 mM substrates and these were assayed in the PIO with and open ﬁlter to measure (a) speciﬁc activity, and (b) kinetics over
50 min.
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View Article Onlinethe additional alkene linkers reduce uorescence quantum yield
of the free acids by about one half per linker.
The emission spectra of the diene linked analogue 5 displayed
two peaks, (Fig. 3a) indicating the existence of two emitting
species in this molecule. Interestingly, the secondary peak (505
nm) is blue-shied compared to native D-luciferin (1). To examine
the states of ionization of the bioluminescent molecules, pH
dependence of uorescence spectra were measured (Fig. 3b–d).
Deprotonation of the 60-hydroxyl results in red-shis of the exci-
tation spectra of all these molecules. Natural D-luciferin (1) red-
shis 40 nm when moving from pH 6.3 to 9.6 (to 385 nm). For
infra-luciferin (4) the excitation spectra is red-shied 47 nm, from
365 nm to 412 nm, but the red-shi for diene linked analogue 5 is
40 nm, also to ca. 412 nm. This suggests an upper limit to the red-
shi of the excitation maxima. Using these data the pKa of the 60-
hydroxy group of D-luciferin (1) was estimated to be ca. 8.7, and
for infra-luciferin (4) and 5 it appeared slightly higher at 8.9.
Whereas the excitation spectra become more intense with
increasing pH for D-luciferin (1) and infra-luciferin (4), they
reduce in intensity with diene linked analogue 5 (reversibly).Light yields, emission kinetics and bioluminescence spectra
of wildtype Photinus pyralis luciferase with 20-2 substituted
luciferins
Light emission with analogues infra-luciferin (4) and the diene
linked analogue 5 was measured with puried wildtype (WT)
Photinus pyralis luciferase (Fluc) using the PhotonIMAGER
Optima 3rd generation intensied CCD-containing device. ThisFig. 5 Emission spectra of luciferin and analogues with wild-type Photin
(1) and 2 mM ATP and emission spectra were obtained using the PIO. (b) I
acquire spectra with (5).
This journal is © The Royal Society of Chemistry 2017instrument has good spectral sensitivity to visible and near-
infrared (nrIR) wavelengths of light. Over 50 min, WT Fluc
has 3550-times less specic activity with infra-luciferin (4) than
natural D-luciferin (1) and 29 000-times less with the diene
linked analogue 5 (Fig. 4a). WT Fluc also displayed a prominent
decay in emission from approximately 5 min until 10 min with
the analogues 4 and 5 (Fig. 4b), which is not seen with D-lucif-
erin and may be due to product inhibition. It is known that L-
luciferin, the opposite enantiomer to natural D-luciferin, is
a competitive luciferase inhibitor.17 In this work, for ease of
synthesis and to obtain signicant quantities of material, we
developed a racemic synthesis of infra-luciferin (4) and 5. Any
inhibitory eﬀect of either enantiomer of 4 or 5 was not strong
enough to completely inhibit bioluminescence and it would
seem that optical purity is not critical in exploring light emis-
sion of these molecules with wild-type Photinus pyralis lucif-
erase. The prominent decay in emission of 4 and 5 (Fig. 4b) may
be due to inhibition by one of their enantiomers,17 or by the
corresponding oxidised luciferin or their dehydro derivatives.18
We know from the preparation of these compounds that
extended conjugation increases the propensity towards the
formation of the corresponding dehydro species in situ (vide
supra).
The bioluminescence spectra of WT Fluc with compounds 1,
4 and 5 show that infra-luciferin (4) displays a 100 nm lmax red-
shi compared to 1 (Fig. 5a and b) as previously reported.8
However, the bioluminescence emission spectrum of diene
linked analogue 5 is analogous to the uorescence emissionus pyralis luciferase. (a) 0.17 mM Fluc was mixed with 150 mM D-luciferin
nfra-luciferin (4) in same conditions as (a). (c) 3 mMWT Fluc was used to
RSC Adv., 2017, 7, 3975–3982 | 3979
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View Article Onlinespectrum of the free acid of 5 in that there are two peaks, the
major one being slightly blue-shied compared to natural
luciferin and then a minor peak at ca. 800 nm.19Conclusions
We have developed a scalable and convergent synthesis that
reduces the number of linear steps to give infra-luciferin in an
overall yield of 31%. The two step method to prepare 12, by
alkenation with phosphonate 8 followed by DAST mediated
cyclisation, gave a higher overall yield (59%) than directly using
thiazoline-phosphonate 9 (23%). The key phosphonate 8 has
the potential to become a common intermediate in the
synthesis of other conjugated luciferins for investigation as
near-infrared bioluminescent imaging agents. This was
demonstrated by the synthesis of diene linked luciferin
analogue 5. This analogue was found to have a lower quantum
yield of bioluminescence than both D-luciferin (1) and infra-
luciferin (4) and exhibited two peaks in its bioluminescence
spectrum, the major one being slightly blue-shied compared
to natural D-luciferin, and a minor peak at ca. 800 nm. Although
this is an extremely red shied bioluminescent signal, it is weak
and demonstrates the limitations of extended conjugation in
luciferin derivatives with the WT Fluc enzyme.
Current work is aimed at developing an enantioselective
synthesis of infra-luciferin (5) to investigate any dependence of
bioluminescence on optical purity and a study of the enantio-
meric purity of the material during in vitro and in vivo assays.
We are also currently using this synthetic route to synthesise
other infra-luciferin analogues and are developing luciferases
that improve bioluminescence.Experimental
Methyl 2-(2-(diethoxyphosphoryl)ethanethioamido)-3-
hydroxypropanoate (8)
A solution of serine methyl ester (2.54 g, 16.3 mmol) in DCM (130
mL) was treated with Et3N (2.27 mL, 16.3 mmol) and stirred until
completely dissolved (10 min). Aer this time a solution of ethyl
2-(diethoxyphosphoryl)ethanedithioate (7) (3.80 g, 14.8 mmol) in
DCM (30 mL) was added dropwise. The reaction was stirred at rt
for 3 d until 31P NMR showed no further conversion to the
product. The reaction mixture was concentrated in vacuo to give
a yellowish oil. Purication was achieved by ash column chro-
matography (0–10% MeOH/EtOAc) to give 8 (4.27 g, 92%) as
a yellow oil. Rf ¼ 0.42 (75% EtOAc/Pet. ether); 1H NMR (CDCl3,
300) d 4.17 (m, 5H), 4.00 (dd, J ¼ 11.8, 2.8, 1H), 3.82 (s, 3H), 3.49
(m, 2H), 1.35 (m, 6H); 13C NMR (151 MHz, CDCl3) d 193.4, 170.0,
63.3, 61.4, 60.8, 52.9, 45.1, 16.5; 31P NMR (121 MHz, CDCl3)
d 21.4; IR nmax 3301, 2983, 1744, 1435, 1231, 1049, 1023, 975
cm1; HRMS (ES+) C14H21NOPS2 calcd 314.0802, found 314.0803.1-[(Diethylphosphono)methyl]-(4-methoxycarbonyl-4,5-
dihydro)thiazole (9)
A solution of 8 (1.46 g, 4.66 mmol) in THF (100 mL) was treated
with PPh3 (2.20 g, 8.40 mmol) followed by DEAD (1.32 mL, 8.403980 | RSC Adv., 2017, 7, 3975–3982mmol) and stirred at rt for 4 h. Solvent was removed in vacuo
and the resultant oil puried by ash column chromatography
(5–10% MeOH/EtOAc) to give 9 (1.38 g, 85%) as an yellow oil. Rf
¼ 0.40 (5% MeOH/EtOAc); 1H NMR (CDCl3, 300) d 5.08 (dd, J ¼
15.1, 9.4, 1H), 4.25–4.03 (m, 4H), 3.80 (s, 3H), 3.71–3.50 (m, 2H),
3.31–3.10 (m, 2H), 1.33 (t, J ¼ 7.1, 6H); 13C NMR (CDCl3, 150)
d 171.1, 165.7, 77.8, 62.9, 52.9, 36.5, 33.5, 16.5; 31P NMR (121
MHz, CDCl3) d 20.6; IR nmax 2980, 1742, 1255, 1023 cm
1; HRMS
(ES+) C10H19NO5S calcd 296.0722, found 296.0719.
6-(b-Methoxyethoxymethyl ether)-2-formylbenzothiazole (10)
A solution of 6-(b-methoxyethoxymethyl ether)-benzothiazole
(600 mg, 2.51 mmol) in THF (20 mL) was cooled to 78 C
and treated with nBuLi (1.97 mL, 2.76 mmol, 1.40 M solution in
hexane) and stirred at 78 C for 20 min. Aer this time DMF
(0.77 mL, 10.0 mmol) was added dropwise and the resultant
solution stirred at 78 C for 2 h. The reaction was quenched
with saturated NaHCO3(aq) (5 mL), taken up in EtOAc (50 mL)
separated and back extracted using EtOAc (2  20 mL). The
organic layers were dried over MgSO4, ltered and concentrated
in vacuo to give 10 (585 mg, 87%) as a yellow oil. Rf ¼ 0.32 (20%
EtOAc/Pet. ether); 1H NMR (CDCl3, 600) d 10.12 (s, 1H), 8.13 (d, J
¼ 9.0, 1H), 7.67 (d, J¼ 2.4, 1H), 7.31 (dd, J¼ 9.0, 2.4, 1H), 5.39 (s,
2H), 3.87–3.88 (m, 2H), 3.58–3.59 (m, 2H), 3.39 (s, 3H); 13C NMR
(CDCl3, 150) d 185.3, 163.7, 157.9, 149.0, 138.4, 126.7, 119.2,
107.4, 94.0, 71.7, 68.2, 59.2; IR nmax 2921, 2876, 2817, 1687, 1599,
1487, 1417, 1325, 1251, 1103, 1043, 1027, 987 cm1; HRMS (ES+)
C12H14NO4S calcd 268.0644, found 268.0648.
(E)-Methyl 2-(3-(6-b-methoxyethoxymethyl ether-benzothiazol-
2-yl)prop-2-enoylthioamido)-3-(hydroxy)propononate (11)
A solution of 8 (67 mg, 0.210 mmol) in MeCN (1 mL) was treated
with LiCl (10 mg, 0.240 mmol), stirred 5 min, followed by DBU
(36 mg, 0.240 mmol). Aer stirring at rt for 5 min a solution of
10 (64 mg, 0.240 mmol) in MeCN (1.5 mL) was added dropwise
and stirred at rt for 2.5 h. The solution was ltered and
concentrated in vacuo. Purication was achieved by ash
column chromatography (75% EtOAc/hexanes) to give 11
(57 mg, 63%) as an orange oil. Rf ¼ 0.31 (75% EtOAc/Pet. ether);
1H NMR (CDCl3, 600) d 8.95 (br, 1H), 8.02 (d, J ¼ 9.0, 1H), 7.95
(d, J ¼ 15.2, 1H), 7.60 (d, J ¼ 2.4, 1H), 7.45 (d, J ¼ 15.1, 1H), 7.25
(dd, J¼ 9.0, 2.5, 1H), 5.38–5.40 (m, 1H), 5.36 (s, 2H), 4.20 (dd, J¼
11.7, 3.3, 2H), 3.86–3.89 (m, 2H), 3.85 (s, 3H), 3.58–3.61 (m, 2H),
3.38 (s, 3H); 13C NMR (CDCl3, 150) d 192.8, 170.0, 163.0, 156.8,
135.6, 135.0, 131.0, 123.3, 119.1, 107.4, 94.0, 77.2, 71.6, 68.2,
62.1, 60.5, 59.2, 53.2; IR nmax 3300, 1925, 1740, 1597, 1194, 1077,
991, 822 cm1; HRMS (ES+) C18H23N2O6S2 calcd 427.0998, found
427.0999.
6-(b-Methoxyethoxymethyl ether)-2-(2-(4-methoxycarbonyl-
4,5-dihydrothiazol-2-yl)ethenyl)benzothiazole (12)
A solution of 11 (230 mg, 0.54 mmol) in DCM (3 mL) was cooled
to 78 C and treated with DAST (85 mL, 0.64 mmol). Aer
stirring at 78 C for 30 min the reaction was quenched with
saturated NH4Cl(aq) solution (3.5 mL). The layers were separated
and the aqueous layer was extracted with DCM (2 10 mL). TheThis journal is © The Royal Society of Chemistry 2017
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View Article Onlinecombined organic layers were washed with brine (30 mL), dried
(Na2SO4), ltered and concentrated. Purication was achieved
by ash column chromatography (75% EtOAc/hexanes) to give
12 (206 mg, 94%) as an orange waxy solid. Rf¼ 0.40 (75% EtOAc/
Pet. ether); 1H NMR (600 MHz, CDCl3) d 7.93 (d, J ¼ 9.0, 1H),
7.57 (d, J ¼ 2.4, 1H), 7.41 (d, J ¼ 16.2, 1H), 7.33 (d, J ¼ 16.2, 1H),
7.20 (dd, J ¼ 8.9, 2.4, 1H), 5.34 (s, 2H), 5.25 (t, J ¼ 9.3, 1H), 3.88–
3.82 (m, 5H), 3.73–3.60 (m, 2H), 3.57 (m, 2H), 3.38 (s, 3H); 13C
NMR (CDCl3, 150) d 171.0, 169.3, 162.6, 156.4, 149.2, 136.5,
135.0, 129.3, 124.5, 117.8, 107.4, 94.0, 78.1, 71.7, 68.0, 59.2, 53.1,
35.1; IR nmax 2900, 1737, 1597, 1452, 1199, 1102, 991 cm
1;
HRMS (ES+) C18H21N2O5S2 calcd 409.0892, found 409.0894.
6-Hydroxy-2-(2-(4S-methoxycarbonyl-4,5-dihydrothiazol-2-yl)
ethenyl)benzothiazole (6)
A solution of 12 (61 mg, 0.220 mmol) in anhydrous TFA (1.5 mL)
was stirred at rt for 3 h. Aer this time saturated NaHCO3(aq)
solution (15 mL) was added until gas evolution ceased, and the
product extracted into EtOAc (3  15 mL) and separated. The
organic layer was dried over NaSO4, stirred 30 min, ltered and
concentrated in vacuo to give 6 (33 mg, 97%) as a pale yellow
solid. Mp 153–157 C; Rf¼ 0.13 (40% EtOAc/Pet. ether); 1H NMR
(600 Hz, MeOD) d 7.82 (d, J¼ 8.9, 1H), 7.41 (d, J¼ 16.1, 1H), 7.31
(d, J ¼ 2.3, 1H), 7.29 (d, J ¼ 16.1, 1H), 7.03 (dd, J ¼ 8.9, 2.5, 1H),
5.33 (t, J¼ 9.0, 1H), 3.81 (s, 3H), 3.72 (dd, J¼ 11.3, 9.6, 1H), 3.70
(dd, J ¼ 11.2, 8.6, 1H). Data agrees with that reported in the
literature.8
6-Hydroxy-2-(2-(4S-carboxy-4,5-dihydrothiazol-2-yl)ethenyl)
benzothiazole (4)
Argon was bubbled through the solvent for 5 min to remove
oxygen before use. A suspension of 6 (50 mg, 0.156 mmol) in
THF/H2O (2 : 1, 3.6 mL) was treated with LiOH$H2O (14.4 mg,
0.671 mmol) and stirred at rt for 5 min. Aer this time the
reaction mixture was diluted with H2O (20 mL), extracted with
EtOAc (2  20 mL) and Et2O (20 mL), the aqueous acidied
using 2 M HCl to pH 3 and extracted with (2  20 mL) and Et2O
(20 mL). The combined nal organics were dried (Na2SO4),
ltered and concentrated to give 4 (44 mg, 92%) as a bright
orange solid. Mp 110 C (dec.); 1H NMR (600MHz, MeOD) d 7.82
(d, J ¼ 8.9, 1H), 7.40 (d, J ¼ 16.1, 1H), 7.31 (d, J ¼ 2.5, 1H), 7.30
(d, J ¼ 16.1, 1H), 7.03 (dd, J ¼ 8.9, 2.4, 1H), 5.30 (t, J ¼ 9.0, 1H),
3.76–3.66 (m, 2H); 13C NMR (MeOD, 150) d 173.3, 162.2, 158.6,
148.5, 138.1, 135.6, 128.8, 125.1, 118.1, 107.4, 78.8, 35.8; IR nmax
3445, 3095, 1507, 1308 cm1; HRMS (ES+) C13H11N2O3S2 calcd
307.0133, found 307.0212.
(E)-3-(6-b-Methoxyethoxymethyl ether-benzothiazol-2-yl)-
prop-2-enal (13)
A solution of 10 (169 mg, 0.632 mmol) in DCM (3 mL) was
treated with (triphenylphosphorarylidene)acetaldehyde
(202 mg, 0.663 mmol) and stirred at rt for 3 h. The crude reac-
tion was directly loaded onto a silica column for purication.
Purication was achieved by ash column chromatography
(20% EtOAc/Pet. ether) to give 13 (156 mg, 84%) as a yellow
solid. Mp 58–61 C; Rf ¼ 0.42 (40% EtOAc/Pet. ether); 1H NMRThis journal is © The Royal Society of Chemistry 2017(CDCl3, 600) d 9.80 (d, J¼ 7.5, 1H), 8.00 (d, J¼ 9.0, 1H), 7.71 (d, J
¼ 16.0, 1H), 7.62 (d, J ¼ 2.4, 1H), 7.24 (dd, J ¼ 9.0, 2.4, 1H), 6.90
(dd, J ¼ 16.0, 7.5, 1H), 5.37 (s, 2H), 3.87–3.88 (m, 2H), 3.58–3.59
(m, 2H), 3.39 (s, 3H); 13C NMR (CDCl3, 150) d 192.6, 161.3, 156.8,
149.5, 143.7, 137.2, 133.7, 125.1, 118.3, 107.3, 94.0, 71.7, 68.1,
59.2; IR nmax 2890, 1679, 1592, 1550, 1253, 1225, 1088, 1040, 965
cm1; HRMS (CI) C14H16NO4S calcd 294.0800, found 294.0805.Methyl 2-(2E,4E-5-(6-b-methoxyethoxymethyl ether-
benzothiazol-2-yl)penta-2,4-dienoylthioamido)-3-(hydroxy)
propononate (14)
Procedure as that for 11 on a 0.142 mmol scale. Purication was
achieved by ash column chromatography (75–100% EtOAc/
hexanes) to give 14 (19 mg, 29%, (49% b.r.s.m.)) as an orange
oil. Rf ¼ 0.42 (70% EtOAc/Pet. ether); 1H NMR (CDCl3, 600)
d 8.27 (br, 1H), 7.89 (d, J ¼ 8.9, 1H), 7.63 (ddd, J ¼ 13.4, 6.9, 3.4,
1H), 7.54 (d, J¼ 2.4, 1H), 7.18 (dd, J¼ 8.9, 2.5, 1H), 7.12–7.16 (m,
2H), 6.60 (d, J¼ 14.5, 1H), 5.44 (dt, J¼ 7.1, 3.1, 1H), 5.34 (s, 2H),
4.22 (dd, J¼ 11.5, 3.2, 1H), 4.16 (dd, J¼ 11.4, 3.1, 1H), 3.78–3.87
(m, 2H), 3.78 (s, 3H), 3.56–3.58 (m, 2H), 3.36 (s, 3H); 13C NMR
(CDCl3, 150) d 194.4, 170.5, 163.9, 156.0, 149.2, 140.8, 136.2,
133.9, 133.6, 132.3, 124.0, 117.7, 107.4, 94.0, 71.7, 67.0, 62.3,
59.8, 59.2, 51.2; IR nmax 3248, 2925, 1739, 1644, 1602, 1554, 1523,
1250, 1201, 1099, 1046, 987 cm1; HRMS (ES+) C20H25N2O6S2
calcd 453.1154, found 453.1158.6-b-Methoxyethoxymethyl ether-2-(4-1E,3E-(4-ethoxycarbonyl-
4,5-dihydrothiazol-2-yl)buta-2,4-dienyl)benzothiazole (15)
Procedure as that for 12 on a 0.075 mmol scale. Purication was
achieved by ash column chromatography (70% EtOAc/
hexanes) to give 15 (23 mg, 71%) as an orange solid. Mp 88–
90 C; Rf ¼ 0.25 (70% EtOAc/Pet. ether); 1H NMR (CDCl3, 600)
d 7.90 (d, J ¼ 8.8, 1H), 7.57 (d, J ¼ 2.4, 1H), 7.19 (dd, J ¼ 8.8, 2.3,
1H), 7.16–7.22 (m, 1H), 7.06 (d, J ¼ 15.5, 1H), 6.97 (dd, J ¼ 15.4,
10.7, 1H), 6.79 (d, J¼ 15.4, 1H), 5.35 (s, 2H), 5.22 (t, J¼ 9.2, 1H),
3.86–3.88 (m, 2H), 3.83 (s, 3H), 3.66 (dd, J ¼ 11.0, 9.2, 1H), 3.57–
3.61 (m, 1H), 3.56–3.58 (m, 2H), 3.39 (s, 3H); 13C NMR (CDCl3,
150) d 171.2, 169.6, 163.6, 156.0, 149.3, 140.3, 136.2, 134.2,
130.8, 129.1, 124.0, 117.6, 107.5, 94.0, 78.2, 71.7, 68.0, 59.2, 53.1,
34.9; IR nmax 2920, 1736, 1650, 1597, 1251, 1200, 1163, 1099,
1046, 986 cm1; HRMS (ES+) C20H23N2O5S2 calcd 435.1048,
found 435.1049.6-Hydroxy-2-(4-1E,3E-(4-methoxycarbonyl-4,5-dihydrothiazol-
2-yl)buta-2,4-dienyl)benzothiazole (16)
Procedure as that for 6 on a 0.053 mmol scale. Purication was
achieved by ash column chromatography (70% EtOAc/
hexanes) to give 16 (16 mg, 87%) as a yellow solid. Mp 168–
170 C; Rf¼ 0.45 (100% EtOAc); 1H NMR (MeOD, 600) d 7.76 (d, J
¼ 8.9, 1H), 7.29 (d, J¼ 2.4, 1H), 7.25–7.31 (m, 1H), 7.08–7.18 (m,
2H), 6.99 (dd, J¼ 15.4, 2.4, 1H), 6.78 (d, J¼ 15.4, 1H), 5.27 (t, J¼
9.0, 1H), 3.81 (s, 3H), 3.67 (dd, J ¼ 11.2, 9.4, 1H), 3.63 (dd, J ¼
11.1, 8.6, 1H); 13C NMR (MeOD, 150) d 172.6, 172.3, 164.2, 158.1,
148.4, 142.2, 135.5, 131.9, 129.3, 124.5, 117.7, 107.4, 78.6, 53.1,
35.3; IR nmax 3029, 2951, 2921, 1733, 1610, 1596, 1556, 1271,RSC Adv., 2017, 7, 3975–3982 | 3981
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View Article Online1201, 1172, 1046, 974 cm1; HRMS (ES+) C16H15N2O3S2 calcd
347.0524, found 347.0536.
6-Hydroxy-2-(4-1E,3E-(4-carboxy-4,5-dihydrothiazol-2-yl)buta-
2,4-dienyl) benzothiazole (5)
Procedure as that for 4 on a 0.043 mmol scale to give 5 (5 mg,
35%) as a brown solid (unoptimised). For characterization
purposes a suspension of 16 (2 mg, 0.0057 mmol) in D2O (0.2
mL) was treated with LiOH (0.28 mg, 0.014 mmol) and stirred
for 5 min, aer this time NMR indicated complete conversion to
product. 1H NMR (D2O, 600, solvent suppression of largest
peak) d 7.73 (d, J ¼ 8.9, 1H), 7.29 (dd, J ¼ 15.3, 10.6, 1H), 7.18
(dd, J ¼ 15.3, 10.8, 1H), 7.15 (d, J ¼ 15.4, 1H), 7.10 (d, J ¼ 2.3,
1H), 6.90 (dd, J¼ 8.8, 2.3, 1H), 6.82 (d, J¼ 15.3, 1H), 5.11 (dd, J¼
9.3, 7.9, 0.25H), 3.72 (d, J ¼ 11.0, 1H), 3.52 (d, J ¼ 11.1, 1H); 13C
NMR (D2O, 150) d 179.3, 171.9, 167.2, 161.9, 143.7, 141.9, 137.7,
134.3, 130.8, 128.1, 123.4, 121.6, 109.1, 80.1, 36.4; HRMS (ES+)
C15DH12N2O3S2 calcd 334.0440, found 334.0448. There was
evidence of proton/deuterium exchange at the position adjacent
to the carboxylic acid resulting in the signal at d 5.11 only
integrating to 0.25H.
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